Philips announced its plan to lay off 4,000 workers, which is over five per cent of the tech company's workforce. According to CEO Roy Jakobs, the move is intended to boost productivity and agility, (IANS reported), and to realize profitable growth potential and value creation for all the stakeholders. Philips estimates that severance and termination-related costs to be approximately 300...
Beyond Air posted a loss of ($0.73) a share for the quarter, missing analysts’ consensus estimates of ($0.24). In the year-ago quarter, the company posted ($0.24) EPS. Analysts expect Beyond Air earnings per share of -1.18 for for the current year. Beyond Air shares got a price target raise by LADENBURG THALM/SH SH from $17.00 to $23.00 in a research report sent to investors on Wednesday,...
Zomedica's shares have lost around -28% of their value since the company announced the first sale of its Truforma system on March 16. Truforma is a diagnostic platform for dogs and cats, and is Zomedica's first commercial product. On Nov. 13, Zomedica first announced its plans to commercialize Truforma leading to investors driving the company's stock price by +2,600%! Following the massive...
For years — decades even— traders have been scouring charts on a daily basis in search of pattern formations.The thinking has been that if you found a pattern early in its formation, maybe you could capitalize on a trade by predicting where the security was headed.
The Cup-and-Handle pattern is a great example of how this works.
Abbott Laboratories unveiled a $5, 15-minute coronavirus test that was given an emergency approval from the U.S. government.
The healthcare and medical device company’s portable antigen test, is to be called BinaxNOW.In 49 of 79 cases where ABT's Momentum Indicator exceeded 0, its price rose further within the subsequent month.
Abbott Laboratories said that it’s expecting to send out 4 million of its new coronavirus antibody test kits this month.
The test is designed to reveal whether a person had been infected with covid-19 and whether he or she is now asymptomatic or recovered.
“It’s clear that the demand for testing is big; it’s not going to go away.” Abbott Chief Executive Robert Ford said during an earnings conference call Thursday.Ford also mentioned in the call that the company plans to increase its shipments to 20 million a month starting June.
While Abbott has already introduced three coronavirus tests in the U.S., Ford indicated that a fourth one is underway.
Abbott Laboratories (NYSE: ABT) is classified as a diversified medical company because the company develops generic pharmaceuticals and nutritional supplements, but it also develops diagnostic systems.The current political environment has brought attention to the costs of prescription drugs in the United States and with Abbott developing generic drugs and also having the cushion of developing nutritional supplements and diagnostic systems as well, it could actually benefit from additional regulation in the industry.
Regardless of what happens going forward, the company has performed very well in recent years and so has the stock.
The company also raised its full-year guidance.
The healthcare company’s adjusted earnings for the quarter came in at was 82 cents, topping the FactSet consensus estimate of 80 cents.
Quarterly revenue increased +2.7% year-over-year to $7.979 billion, but fell slightly short of the $7.997 billion that analysts polled by FactSet had expected.
Abbott’s sales from its nutrition unit rose +0.9% to $1.875 billion.FreeStlye Libre sales, in particular, surged 72.9% on a reported basis to $433 million over the quarter.
Looking ahead, Abbott now expects its full-year earnings per share to a range of $3.21 to $3.27, up from prior forecast of a range of $3.15 to $3.25.
Medtronic (NYSE: MDT) has a definitive deal to acquire privately held Titan Spine, makers of titanium inter-body implant and surface technology.
Read More...
Abbott Laboratories beat expectations of first quarter earnings .
The healthcare company reported adjusted earnings of 63 cents per share for the first quarter, which exceeded analysts’ estimates of 61 cents per share (based on FactSet survey). Its revenue came in at $7.5 billion, compared to analysts’ expectation of $7.48 billion.
For the second quarter, Abbott has forecasted earnings to range between 79 cents and 81 cents per share, in line with analysts' expectations of 80 cents.
For the full year, the company expects earnings of $3.15 to $3.25 per share, which is also in line with Wall Street's $3.21 expectation.
Its minimally invasive therapies business, which makes surgical instruments and endoscopy products, was a major contributor to the sales performance.
Medtronic projects its full-year earnings to be in the range of $5.14 and $5.16 per share – that’s higher compared to its previous predicted range of $5.10 to $5.15 per share.Analysts are expecting earnings of $5.12 per share.
The company also revised its 2019 organic revenue growth forecast range upwards to 5.25% - 5.5 %, albeit with a caveat that a strong dollar would affect its full-year revenue by about $425 million to $475 million.
Omar Ishrak, Medtronic chairman and chief executive officer indicated that the company’s business diversification was an advantage in generating the strong sales figures.
Morgan Creek Digital has scored what it says is probably the first investment in the crypto asset universe from a U.S. pension fund.
Read more...
American Express reported fourth-quarter revenue on Thursday that narrowly missed analysts' expectations and an earnings profit after reporting a loss for the same period a year ago.Read More...
Medical device company Tandem Diabetes Care (Nasdaq: TNDM) had an incredible run for the first eight and a half months of 2018.The stochastic readings also just made a bearish crossover on Wednesday.
Something that could be holding the stock back at this point is its fundamental indicators.
Among the patterns that the Tickeron Pattern Search Engine identifies is one called Three Rising Valleys.In those instances, the success rate was 54.5%.
The average gain on successful trades was 14.13%.
The biopharma company Amarin might be winning hearts (and saving them) with its formulation of fish oil, called Vascepa.
Potentially mitigating skepticism surrounding the long-term benefits of omega-3 fatty acids, tests conducted by Amarin support Vascepa’s potential.The results could potentially hail Amarin’s Vascepa as a sought-after cardiovascular therapy for Americans, which makes one wonder if the stock price could follow.